The Value of Intracameral Injection of Bevacizumab for Treatment of Rubeosis Iridis in Neovascular Glaucoma in Nassiryah City
European Journal of Molecular & Clinical Medicine,
2020, Volume 7, Issue 2, Pages 257-264
AbstractPurpose: This work targets assessing the estimation of intracameral bevacizumab
infusion in treatment of rubeosis iridis in neovascular glaucoma.
Patients and strategies: A planned report was done on 30 eyes of 30 patients with
rubeosis iridis. Intracameral infusion of bevacizumab was infused for all patients. Iris
flourescein angiography and specular microscopy were performed to all patients
preoperatively and postoperatively. Patients were followed up at five days, one month, a
quarter of a year, and a half year spans following the system.
Results: Iris fluorescein angiography demonstrated neovascularization relapse just in the
early development. Notwithstanding, specular microscopy indicated practically stable
endothelial trustworthiness aside from a couple of cases.
Conclusion: The utilization of intracameral bevacizumab for rubeosis iridis still needs
more preliminaries to build up long haul security and viability in retinal ischemia and
- Article View: 132
- PDF Download: 308